Vanda Pharmaceuticals Inc. (VNDA)

20.36
0.22 1.09
NASDAQ : Health Technology
Prev Close 20.14
Open 20.24
Day Low/High 20.03 / 21.00
52 Wk Low/High 13.88 / 33.44
Volume 936.94K
Avg Volume 851.50K
Exchange NASDAQ
Shares Outstanding 52.45M
Market Cap 1.11B
EPS 0.50
P/E Ratio 87.96
Div & Yield N.A. (N.A)

Raise Cash Ahead of Fed News

The market could take off on a bullish surprise, but binary events are always tough to trade.

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized

Investors eyeing a purchase of Vanda Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 80 cents.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA)

Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA)

Vanda Pharmaceuticals (Nasdaq:VNDA) has been downgraded by TheStreet Ratings from from a hold to sell.

Biotech Stock Mailbag: Exelixis

Biotech Stock Mailbag: Exelixis

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade significantly higher from current levels.

Biotech Stock Mailbag: Bio-Hazards

Biotech Stock Mailbag: Bio-Hazards

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA)

Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA)

Vanda Pharmaceuticals (Nasdaq:VNDA) has been upgraded by TheStreet Ratings from a sell to hold.

Vanda's Fanapt Falls Flat

Vanda's Fanapt Falls Flat

Vanda's schizophrenia drug closes 2010 with just $31 million in sales, far below expectations.

Clinical Data: Bulls and Bears Round Two

Clinical Data: Bulls and Bears Round Two

Clinical Data's new antidepressant is approved but bulls want the company to be sold for an even higher premium while bears say any deal is unlikely.

10 Unloved Stocks to Rise Up to 120%

10 Unloved Stocks to Rise Up to 120%

These five-star stocks trade at huge discounts to fair value and could soar in 2011.

Biotech Stock Mailbag - Titan Pharma

Biotech Stock Mailbag - Titan Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Avanir Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag - 2Q Updates

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Amarin Pharma

Biotech Stock Mailbag: Amarin Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.

Vanda Schizophrenia Drug Gets Rotten Review

Vanda's Fanapt is treated roughly in the new psychiatrists' 'bible', further hurting the drug's launch efforts.

Biotech Calendar: Key Dates for May

Here's a list of May's potentially stock-moving biotech events.

Biotech Stock Mailbag: Labopharm

Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.

Biotech Earnings: Large-Cap Preview

Biotech Earnings: Large-Cap Preview

Biotech's first-quarter earnings season kicks off next week. Here are earnings summaries for nine revenue-generating biotech stocks.

Biotech Stock Mailbag: Generex, Part II

Biotech columnist Feuerstein answers readers' questions about Generex, Cell Therapeutics and other stocks.

Call-Selling in Vanda Pharma

Call-Selling in Vanda Pharma

Expecting limited upside, a call seller boosts volume in Vanda Pharmaceuticals.

Biotech's 2009 Movers & Shakers: BioBuzz

A look back at 2009's best- and worst-performing bitoech stocks.

Nasdaq 2009 Winners & Losers

Nasdaq 2009 Winners & Losers

Diedrich Coffee is up 9,580%, RHI Entertainment lands at the bottom, down 96%.

Vanda's Fanapt Deal Just Okay: BioBuzz

Vanda's Fanapt Deal Just Okay: BioBuzz

Bulls were hoping for a Vanda takeover.

Novartis to Market Vanda's Fanapt Drug

Novartis to Market Vanda's Fanapt Drug

Vanda Pharmaceuticals entered into an exclusive license agreement with Novartis to commercialize and develop schizophrenia drug Fanapt in the U.S. and Canada.

Novartis, Vanda In Drug Deal Worth Up To $265M

Novartis, Vanda In Drug Deal Worth Up To $265M

Novartis to pay Vanda up to $465 million for rights to sell schizophrenia drug in US, Canada

Bullish Case for Vanda Loses Steam

Bullish Case for Vanda Loses Steam

Vanda's chances of getting acquired seem to be drying up, according to two analysts.

Biotech Stock Mailbag: Genta Takes Another Stab

Biotech Stock Mailbag: Genta Takes Another Stab

Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.

Weighing Arena's Obesity Drug: Biotech Mailbag

Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.

TheStreet Quant Rating: C+ (Hold)